At the International AIDS Society-USA course in Denver in May 2002, Donna E. Sweet, MD, discussed issues related to the ongoing question of when to initiate antiretroviral therapy in HIV-infected individuals and factors in selecting an initial drug regimen. Current treatment guidelines offer some consensus on the question of timing. Selection of the initial therapy focuses on the choice between regimens based on nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, or protease inhibitors.

Download full-text PDF

Source

Publication Analysis

Top Keywords

antiretroviral therapy
8
reverse transcriptase
8
transcriptase inhibitors
8
initial antiretroviral
4
therapy international
4
international aids
4
aids society-usa
4
society-usa course
4
course denver
4
denver 2002
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!